Memorial Sloan Kettering Cancer Center – MSKCC shared a post on X:
“A new era in the treatment of muscle-invasive bladder cancer (MIBC) is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard of care in the perioperative treatment of cisplatin-ineligible or cisplatin-refusing patients.
We spoke with David H Aggen, a genitourinary medical oncologist and cellular therapist at Memorial Sloan Kettering Cancer Center (MSK), to discuss the evidence supporting this potential new standard-of-care and the groundbreaking news from the IMVigor011 study, the first prospective circulating tumor DNA (ctDNA) trial in MIBC announced at ESMO Congress 2025.
More posts about Bladder Cancer.